Impact of a history of metastases or synchronous metastases on survival in patients with locally recurrent rectal cancer.
distant metastases
locally recurrent rectal cancer
metastasis-free survival
overall survival
prognosis
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
28
12
2020
received:
03
11
2020
accepted:
13
01
2021
pubmed:
22
1
2021
medline:
1
9
2021
entrez:
21
1
2021
Statut:
ppublish
Résumé
Patients with locally recurrent rectal cancer (LRRC) frequently present with either synchronous metastases or a history of metastases. This study was conducted to evaluate whether LRRC patients without metastases have a different oncological outcome compared to patients with a history of metastases treated with curative intent or patients with potentially curable synchronous metastases. All consecutive LRRC patients who underwent intentionally curative surgery between 2005 and 2017 in a large tertiary hospital were retrospectively reviewed and categorized as having no metastases, a history of (curatively treated) metastases or synchronous metastases. Patients with unresectable distant metastases were excluded from the analysis. Of the 349 patients who were analysed, 261 (75%) had no metastases, 42 (12%) had a history of metastases and 46 (13%) had synchronous metastases. The 3-year metastasis-free survival was 52%, 33% and 13% in patients without metastases, with a history of metastases, and with synchronous metastases, respectively (P < 0.001) A history of metastases did not influence overall survival (OS), but there was a trend towards a worse OS in patients with synchronous metastases compared with patients without synchronous metastases (hazard ratio 1.43; 95% CI 0.98-2.11). LRRC patients with a history of curatively treated metastases have an OS comparable to that in patients without metastases and should therefore be treated with curative intent. However, LRRC patients with synchronous metastases have a poor metastasis-free survival and worse OS; in these patients, an individualized treatment approach to observe the behaviour of the disease is recommended.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1120-1131Informations de copyright
© 2021 The Association of Coloproctology of Great Britain and Ireland.
Références
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-422.
Van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol. 2013;24(7):1762-9.
Kok EN, Havenga K, Tanis PJ, de Wilt JHW, Hagendoorn J, Peters FP, et al. Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer. Br J Surg. 2020;107(5):537-45.
Dresen RC, Gosens MJ, Martijn H, Nieuwenhuijzen GA, Creemers GJ, Daniels-Gooszen AW, et al. Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol. 2008;15(7):1937-47.
Alberda WJ, Verhoef C, Schipper MEI, Nuyttens JJ, Rothbarth J, De Wilt JHW, et al. The importance of a minimal tumor-free resection margin in locally recurrent rectal cancer. Dis Colon Rectum. 2015;58(7):677-85.
Bosman SJ, Holman FA, Nieuwenhuijzen GAP, Martijn H, Creemers GJ, Rutten HJT. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg. 2014;101(10):1280-9.
Nielsen MB, Laurberg S, Holm T. Current management of locally recurrent rectal cancer. Colorectal Dis. 2011;13(7):732-42.
van Zoggel DMGI, Bosman SJ, Kusters M, Nieuwenhuijzen GAP, Cnossen JS, Creemers GJ, et al. Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer. Br J Surg. 2018;105 4:447-52.
Voogt ELK, van Zoggel DMGI, Kusters M, Nieuwenhuijzen GAP, Bloemen JG, Peulen HMU, et al. Improved outcomes for responders after treatment with induction chemotherapy and chemo(re)irradiation for locally recurrent rectal cancer. Ann Surg Oncol. 2020;27(9):3503-13. https://doi.org/10.1245/s10434-020-08362-4
van den Brink M, Stiggelbout AM, van den Hout WB, Kievit J, Klein Kranenbarg E, Marijnen CAM, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22(19):3958-64.
Detering R, Karthaus EG, Borstlap WAA, Marijnen CAM, van de Velde CJH, Bemelman WA, et al. Treatment and survival of locally recurrent rectal cancer: a cross-sectional population study 15 years after the Dutch TME trial. Eur J Surg Oncol. 2019;45(11):2059-69.
Hagemans JAW, van Rees JM, Alberda WJ, Rothbarth J, Nuyttens JJME, van Meerten E, et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol. 2020;46(3):448-54.
Martin TA, Ye L, Sanders AJ, Lane J, Jiang WG. Cancer invasion and metastasis: molecular and cellular perspective. In: Madame Curie Bioscience Database. Austin (TX): Landes Bioscience; 2000-2013. https://www.ncbi.nlm.nih.gov/books/NBK164700/
Leong L. Clinical relevance of targeting cancer metastases. In: Madame Curie Bioscience Database. Austin (TX): Landes Bioscience; 2013. p. 8-10. https://www.ncbi.nlm.nih.gov/books/NBK154382/
Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, et al. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. Br J Radiol. 2017;90(1076):20170134.
Schurr P, Lentz E, Block S, Kaifi J, Kleinhans H, Cataldegirmen G, et al. Radical redo surgery for local rectal cancer recurrence improves overall survival: a single center experience. J Gastrointest Surg. 2008;12:1232-8.
Cyr DP, Zih FS, Wells BJ, Swett-Cosentino J, Burkes RL, Brierley JD, et al. Long-term outcomes following salvage surgery for locally recurrent rectal cancer: a 15-year follow-up study. Eur J Surg Oncol. 2020;46(6):1131-7.
Hartley JE, Lopez RA, Paty PB, Wong WD, Cohen AM, Guillem JG. Resection of locally recurrent colorectal cancer in the presence of distant metastases: can it be justified? Ann Surg Oncol. 2003;10:227-33.
You YN, Habiba H, Chang GJ, Rodriguez-Bigas MA, Skibber JM. Prognostic value of quality of life and pain in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2011;18(4):989-96. https://doi.org/10.1245/s10434-010-1218-6
Verhoef C, Van Der Pool AEM, Nuyttens JJ, Planting AST, Eggermont AMM, De Wilt JHW. The “liver-first approach” for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum. 2009;52(1):23-30.
Ayez N, Burger JWA, Van Der Pool AE, Eggermont AMM, Grunhagen DJ, De Wilt JHW, et al. Long-term results of the “liver first” approach in patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum. 2013;56(3):281-7.
Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy. Ann Surg. 2004;240(6):1052-64.